



Press Release

BioApex, s.r.o. signs a Joint Patent Agreement with the Palacky University, Olomouc, Czech Republic, and the University of Bialystok, Bialystok, Poland

Olomouc, Czech Republic (April 15, 2010) – BioApex, s.r.o., a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat serious cell cycle related disorders, including various cancers, today announced that it has signed a joint patent agreement with the Palacky University, Olomouc, Czech Republic, and the University of Bialystok, Bialystok, Poland. Under the joint patent agreement, BioApex will be responsible, in close cooperation with both universities, for the advanced research, development and commercialisation of proprietary anticancer compounds derived from new saponins emanating from the research of the University of Bialystok.

About BioApex, s.r.o.: BioApex's intellectual property addresses the very broad fields of cell division related disorders and, besides cancers, includes restenosis, glomerulonephritis, type I diabetes, gout and viral disorders. BioApex owns a proprietary portfolio of small molecule-like compounds that exhibit promising anticancer properties. BioApex believes that, to date, there are no commercially available compounds that combine the same mode of action, effectiveness and minimal side effects.

BioApex plans to initially advance a group of promising compounds on which the design, *in vitro* testing and preclinical trials have been completed, to clinical testing. A second group of compounds will be taken through pharmacokinetic studies and pre-clinical efficacy trials to determine development priorities. BioApex's business model - a tiered strategy with some compounds in an advanced stage of development and encouraging results to date and some compounds in the pipeline for development – is tailored to attract both, industry "partners" and – in addition to governmental grants and loans - private equity to fund operations. With limited resources focused on research and development, BioApex plans to partner with strong pharmaceutical companies that have established sales and marketing channels in BioApex's target areas.

For more information, visit the company's website at www.bioapex.cz